To evaluate the efficacy of intravitreal bevacizumab injection (IVB) for the treatment of chronic, recurrent, or atypical central serous chorioretinopathy (CSC).Methods
Forty-nine eyes of 49 patients who were diagnosed with chronic, recurrent, or atypcial CSC and treated with intravitreal injection of 1.25 mg/0.05 ml bevacizumab, were included for this retrospective study. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed at baseline, 3, 6, 9, and 12 months after initial IVB.Results
Patients received the mean of 2.16±1.34 IVB during the mean follow-up period of 11.8±7.4 months, and 20.4% of patients had recurrent episode after initial resolution of subretinal fluid in this period. The mean baseline BCVA was 0.27±0.26 logarithm of minimum angle of resolution, and the mean baseline CMT was 353 ± 129 um. BCVA was significantly improved to 0.16 ± 0.18 (P = 0.005) and 0.14 ± 0.12 (P = 0.000) at 3 and 6 months, respectively. However, the improvement of BCVA was not significant at 9 months and 12 months. CMT was significantly reduced throughout the follow-up period and 216±101 um (P = 0.008) at 12 months.Conclusion
Intravitreal bevacizumab injection may be an effective treatment option for patients with chronic, recurrent, or atypical CSC. Further prospective, long-term studies are warranted.